Medtronic's Endeavor DES (drug-eluting stent) gains market approval in China:
This article was originally published in Clinica
Medtronic has received regulatory approval for its Endeavor drug-eluting stent (DES) from the government of the People's Republic of China. The zotarolimus (ABT-578) delivering stent is built from a cobalt alloy, based on the same platform as the Driver, its bare metal stent product. It is coated with phosphorylcholine, a polymer which mimics the outside surface of a red blood cell, in order improve healing response. The DES market in China currently stands at around $100m, and some 70,000 implants are performed every year, said the Santa Rosa, California-based firm. The firm received CE-marking for the stent in July 2005, and hopes for PMA approval in the US during 2007.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.